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Purpose: Aortic stenosis (AS) is a disease process akin to atherosclerosis
and has been linked to several risk factors for coronary artery disease (CAD).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory
biomarker secreted in the atherosclerotic plaque. We hypothesized a relation-
ship between serum Lp-PLA2, plasma oxidized LDL (oxLDL) and AS, in
contrast with CAD.
Methods: Between December 2009 and June 2010, from 494 subjects
scheduled for diagnostic coronary angiography, we selected 234 patients
(71.2% men) included into 2 groups: Group “CAD”: patients with only CAD
and Group “AS”: patients with AS and normal coronary arteries. Lp-PLA2
mass was assessed in serum with a Plac® – test turbidimetric immunoassay.
Control Lp-PLA2 values were specifically obtained in 61 subjects aged
44.5±17.6y without cardiovascular risk factors or cardiac treatment.
Results: In healthy controls, Lp-PLA2 was 163±43 μg/L (men: 166±45 μg/L;
women: 159±39 μg/L, non significant). Lp-PLA2 were significantly higher in
patients than in controls (219.2±49.1 vs 163.0±43.0; p=0.01). Lp-PLA2
increased in AS-patients, and were not significantly different than CAD-
patients (217.3±44.5 vs. 220.4±51.9, respectively; NS). Moreover, Lp-PLA2
levels were similar in patients with single-vessel atherosclerosis (215.2±52.0)
but significantly lower than in patients with three-vessel atherosclerosis
(251.9±5.7 μg/L; p=0.03).
OxLDL levels were 42±13 U/L, which was within normal values. oxLDL
values were 46±12 and 38±12 U/L for AS-patients and CAD-patients, respec-
tively, (p<0.0001). Circulating oxLDL levels were not affected by gender, dia-
betes or hypertension but were significantly correlated with serum apoB,
LDL-cholesterol, triglycerides and ApoA-I. We found no correlation between
Lp-PLA2 and oxLDL. Patients on statin treatment had significantly lower
plasma oxLDL levels than patients without any hypolipidemic treatment.
Conclusion: We report for the first time that high serum levels of Lp-
PLA2 were associated with severe AS. This could have practical implications
because statins and renin-angiotensin-aldosteron system inhibitors seemed to
be a promising treatments of AS.
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Introduction: During Ramadan, Muslims fast during the daylight hours
for a month. A pharmacokinetic variability of several medications can
occurred in this period. However, the effect of Ramadan fasting on INR (Inter-
national normalized ratio) is unknown.
Aim of this study: was to evaluate the fasting Ramadan effect on the vari-
ability of the INR in patients treated at long term with oral anticoagulant.
Methods: 67 fasting patients (aged 60±11.4 years) treated at long term by
acenocoumarol in the evening who fasted during Ramadan participated in this
open, prospective and single center study. Venous blood samples were taken
1 week before Ramadan (INR1), on the 15st (INR2) and 29th days (INR3) of
Ramadan. Exclusion criteria was an INR1<1.7 or INR1>4.5 before Ramadan
and patient taking twice daily dose.
Results: Compared before Ramadan, the mean INR2 was significantly
increased during the 15th days of Ramadan, 4.1±1.7 vs 2.9±0.8, respectively
(p<0.001). A Vitamin K antagonist overdose (INR2>5) was obtained in
19 patients (28.4%). The mean variation of INR2 during this first period was
+46.5% (–35%, +256.4%). We excluded for the third measure all patients with
an INR2>5. The mean INR3 (n=42 pts) was significantly higher than the
INR2, 3.4±0.88 vs 2.9±0.6 (p<0.0001). Compared to INR2, the mean variation
of INR3 during this second period was +16.1% (–29.6%, +114.4%). Finally
during Ramadan a VKA overdose was noted in 31.3% of cases. By multi-
variate analysis we found two independent predictors factors linked to a high
INR during Ramadan: an initial INR>3 before Ramadan (OR=3.57; p=0.037)
and a dose of acenocoumarol 4 mg (OR=3.5; p=0.041).
Conclusions: At our knowledge this is the first study demonstrate that
intermittent fasting led to increase significantly the level of anticoagulation
during this holy period. After this pilot study, we recommend checking sys-
tematically the INR before and during this period in order to reduce the INR
around 2.
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Purpose: We aimed to assess the long term prognosis associated with
COPD in a contemporary large cohort of pts with established CAD.
Methods: 783 consecutive male pts hospitalized in 2001-2004 for coro-
nary artery disease were considered. The median follow-up was 7.17 years.
Total mortality was predicted with a Cox proportional hazard model.
Results: Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic,
mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean
blood pressure was 139 (20)/84 (11) mmHg and median heart rate was 61 bpm
[Interquatile range (IQR)] [57-70]. Mean HDL cholesterol was 43 mg/dl (11),
mean LDL cholesterol 124 mg/dl (39) and median triglycerides were 147 mg/dl
IQR [109-197]. Mean Cockcroft-Gault creatinine clearance was 87 ml/min
and 11 pts (1.4%) had a severe chronic renal failure (lower than 30 ml/min).
Mean left ventricular ejection fraction was 0.53 (0.13). 88.5% were on anti-
platelet therapy, 75.2% on beta-blocker, 66% on statin therapy and 54.8% on
ACE inhibitors or ARB.
A previous history of COPD was present in 3.5% of pts; 37% of them had
a beta-blocker therapy. The cumulative seven-year total mortality rate was
17.9% in the whole sample (51.8% in pts with COPD and 16.7% in those
without, p<0.001). Among COPD pts with beta-blocker therapy, the mortality
rate was 30% while mortality reached 64.7% in COPD pts without beta-
blocker (p=0.08).
After multivariate adjustment for age, diabetes, tobacco consumption
(none, 40 pack-years, >40 pack-years), heart rate, left ventricular ejection
fraction (>0.5;  0.5 and >0.35; 0.35), duration of CAD, ankle-brachial index
(>0.9; 0.9 and >0.6; 0.6), history of stroke, statin therapy and coronary
revascularization, hazard ratio for all-cause death was 2.22 (95% CI [1.15;
4.26] p=0.016) in pts with COPD compared to those without.
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